ISSN 1004-4140
CN 11-3017/P

CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断研究

王德生, 阚方功, 马周鹏

王德生, 阚方功, 马周鹏. CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断研究[J]. CT理论与应用研究, 2022, 31(5): 655-661. DOI: 10.15953/j.1004-4140.2022.31.05.13.
引用本文: 王德生, 阚方功, 马周鹏. CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断研究[J]. CT理论与应用研究, 2022, 31(5): 655-661. DOI: 10.15953/j.1004-4140.2022.31.05.13.
WANG D S, KAN F G, MA Z P. Diagnostic research of CT combined with serum CA125 and HE4 in ovarian epithelial malignant tumor[J]. CT Theory and Applications, 2022, 31(5): 655-661. DOI: 10.15953/j.1004-4140.2022.31.05.13. (in Chinese).
Citation: WANG D S, KAN F G, MA Z P. Diagnostic research of CT combined with serum CA125 and HE4 in ovarian epithelial malignant tumor[J]. CT Theory and Applications, 2022, 31(5): 655-661. DOI: 10.15953/j.1004-4140.2022.31.05.13. (in Chinese).

CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断研究

详细信息
    作者简介:

    王德生: 男,淄博市博山区医院临床检验科主管技师,主要从事肿瘤的检验与分析研究,E-mail:1420901077@qq.com

    阚方功: 男,淄博市第一医院肿瘤科副主任医师,主要从事肿瘤学的诊断及治疗工作,E-mail:452365020@qq.com

  • 中图分类号: R  816;R  737.31

Diagnostic Research of CT Combined with Serum CA125 and HE4 in Ovarian Epithelial Malignant Tumor

  • 摘要: 目的:探讨CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断价值。方法:以156例卵巢上皮肿瘤(良性72例,恶性84例)为研究对象,术前均行CT和血清肿瘤标志物CA125及HE4检测,将诊断结果与病理学对照,比较CT、CA125、HE4及联合应用对卵巢上皮恶性肿瘤的诊断价值。结果:恶性肿瘤组血清CA125及HE4阳性率均高于良性肿瘤组;CA125诊断恶性肿瘤的灵敏度高于HE4,特异度低于HE4;CA125联合HE4诊断恶性肿瘤的准确率高于CT;CT联合血清CA125及HE4诊断的灵敏度、特异度和诊断准确率分别为95.2%、88.9% 和92.3%,高于单独CT或肿瘤标志物诊断。结论:CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断具有重要价值,有利于早期诊断及准确分期,值得推广应用。
    Abstract: Objective: To explore the diagnostic value of CT combined with serum CA125 and HE4 in ovarian epithelial malignant tumor. Methods: 156 cases of epithelial ovarian tumors (benign 72 cases, malignant 84 cases) were studied. Detections of CT and serum tumor markers CA125 and HE4 were carried out before operation, the diagnostic results were compared with pathology, for the evaluation of the diagnostic value of CT, CA125, HE4 and combined diagnosis in epithelial ovarian tumors. Results: The positive rates of serum CA125 and HE4 of malignant tumor group were higher than those of benign tumor group; The diagnostic sensitivity of CA125 for malignant tumor was higher than HE4, and the specificity was lower than HE4; the diagnostic accuracy of CA125 combined with HE4 for malignant tumor was higher than CT; the sensitivity, specificity and accuracy of CT combined with serum CA125 and HE4 for malignant tumor was 95.2%, 88.9% and 92.3% respectively, and were higher than CT or tumor markers alone. Conclusion: CT combined with serum CA125 and HE4 shows important value in the diagnosis of ovarian epithelial malignant tumor, which is conducive to early diagnosis and precise staging, and is worthy of promoting in application.
  • 卵巢恶性肿瘤中上皮恶性肿瘤最常见,约占卵巢恶性肿瘤的85%~90%,主要包括浆液性囊腺癌、黏液性囊腺癌、透明细胞癌及子宫内膜样癌等[1]。由于恶性程度较高、发展快,该类肿瘤预后往往不佳[2]。同时因为缺乏特异症状和诊断方法,一般难以早期诊断,约 60%~70% 临床确诊时已属晚期[2-3]

    目前 CT和血清肿瘤标志物CA125、HE4在其术前诊断中作用越来越突出[1],我们通过对156例卵巢上皮肿瘤进行研究,探讨CT联合血清CA125及人附睾蛋白4(human epididymis protein 4,HE4)对卵巢上皮恶性肿瘤的诊断价值。

    对2017年1月至2021年5月间于淄博市博山区医院、淄博市第一医院及上海中医药大学附属龙华医院金山分院诊治的156例卵巢上皮肿瘤进行研究。其中良性72例(浆液性囊腺瘤46例,浆液性乳头状囊腺瘤3例,浆液性腺纤维瘤和囊腺纤维瘤1例,黏液性囊腺瘤19例,良性子宫内膜样肿瘤2例,勃勒纳瘤1例),恶性84例,年龄26~71岁,平均年龄(51±13.5)岁。

    入选标准:卵巢原发上皮肿瘤首次确诊,既往无卵巢肿瘤病史及卵巢手术史;未并发其他肿瘤,无肿瘤病史或放、化疗等治疗史;术后经病理学确诊。按国际妇产科联盟(international federation of gynecology and obstetrics,FIGO)对卵巢上皮恶性肿瘤的分期[4],84例恶性肿瘤中Ⅰ期15例,Ⅱ期21例,Ⅲ 期37例,Ⅳ 期11例。其中浆液性囊腺癌61例、黏液性囊腺癌16例、子宫内膜样腺癌5例、透明细胞癌2例。156例病例为连续收集,入组路线图见图1

    图  1  156例卵巢上皮肿瘤病例入组路线图
    Figure  1.  Enrollment diagram of 156 cases of ovarian epithelial tumors

    全部病例清晨采集空腹静脉血约5 mL,自然抗凝后以3000 r/min离10 min,取上清液采用酶联免疫吸附法测定血清中HE4和CA125水平,检测试剂盒购自北京中杉金桥生物有限公司,具体检测步骤严格按照试剂盒说明书进行操作。

    血清CA125和HE4参考值分别设定为0~35 U/mL和0~72 pmol/L,血清CA125>35 U/mL为阳性,≤35 U/mL为阴性;血清HE4高于72 pmol/L为阳性,≤72 pmol/L为阴性。

    采用GE Light Speed 64排CT及Siemens Definition 64排CT进行检查。层厚5 mm,间隔5 mm,扫描范围从膈上至耻骨联合水平,每例均行平扫及动脉、静脉期增强扫描。采用高压注射器经肘静脉注射非离子对比剂碘海醇(300 mgI/mL)80~100 mL,注射流率3 mL/s,注射对比剂后30 s和55 s后分别行动脉期、静脉期扫描。

    由两位高年资CT医师共同进行诊断,参照周康荣等[4]诊断卵巢上皮性恶性肿瘤标准,根据病变的部位、数目、形态、大小、密度、边界、强化特点、与周围结构的关系及腹、盆腔积液等改变进行诊断及分期。

    根据最终病理诊断结果,对CT、血清CA125、HE4及联合诊断的结果进行统计学分析。采用SPSS 20.0软件,计数资料采用(%)表示,组间比较采用χ${}^2 $检验,P<0.05具有统计学意义。

    血清CA125、HE4水平在卵巢上皮良、恶性肿瘤组中阳性率的比较详见表1,结果显示恶性组血清CA125及HE4阳性率均显著高于良性组。

    表  1  血清CA125、HE4在卵巢上皮良、恶性肿瘤组中阳性率的比较
    Table  1.  Comparison among positive rates of serum CA125 and HE4 in benign and malignant ovarian epithelial tumors
    分组CA125HE4
    恶性肿瘤组(n=84)85.71%(72/84)80.95%(68/84)
    良性肿瘤组(n=72)38.89%(28/72)22.22%(16/72)
    χ${} ^2$36.9453.81
    P0.0000.000
    下载: 导出CSV 
    | 显示表格

    CT、血清CA125、HE4单独及联合应用对卵巢上皮恶性肿瘤的诊断结果比较显示CA125诊断的灵敏度高于HE4,HE4诊断特异度高于CA125,CA125联合HE4诊断的准确率高于CT;CT+CA125+HE4诊断准确率高于单独CT或肿瘤标志物诊断(表2),部分病例CT图像见图2图5

    表  2  CT、血清CA125、HE4单独及联合应用对卵巢上皮恶性肿瘤的诊断结果比较
    Table  2.  Comparison among the diagnostic results of CT, serum CA125, HE4 alone and combination application in epithelial ovarian cancer
    诊断项目 灵敏度/%特异度/%阳性预测值/%阴性预测值/%准确率/%
    CA125     85.71a61.1172.0078.5774.36
    HE4      80.9577.78b80.95b77.7879.49b
    CA125+HE4  90.48c83.33c86.36c88.24c87.18c
    CT      83.3380.5683.3380.5682.05
    CT+CA125+HE495.24d88.89d90.91d94.18d92.31d
    χ2      9.8618.5912.999.9921.30
    P       0.0430.0010.0110.0410.000
     注:a-高于HE4;b-高于CA125;c-高于CA125、HE4及CT;d-高于CA125、HE4、CA125+HE4及CT。
    下载: 导出CSV 
    | 显示表格
    图  2  46岁女性,右侧卵巢黏液性囊腺癌
    Figure  2.  A 46-year-old female, mucinous cystadenocarcinoma in the right ovary
    图  3  70岁女性,右侧卵巢浆液性囊腺癌
    Figure  3.  A 70-year-old female, serous cystadenocarcinoma in the right ovary
    图  4  43岁女性,左侧卵巢透明细胞癌
    Figure  4.  A 43-year-old female,clear cell carcinoma in the left ovarian
    图  5  55岁女性,右侧卵巢子宫内膜样腺癌
    Figure  5.  A 55-year-old female, endometrioid adenocarcinoma in the right ovarian

    卵巢恶性肿瘤致死率居女性生殖系统恶性肿瘤之首[4]。该类肿瘤主要包括上皮细胞来源恶性肿瘤、性索间质来源恶性肿瘤、生殖细胞来源恶性肿瘤及转移性肿瘤,其中绝大多数为上皮细胞来源,以浆液性囊腺癌最为多见,其他尚有黏液性囊腺癌、透明细胞癌及内膜样腺癌、未分化癌等[5-6]。由于恶性肿瘤5年生存率由发病早期的90% 下降至晚期的25%~30%,因而及时确诊并积极治疗是改善预后、延长生存的关键[6-7]

    CA125是一种高分子质量的糖蛋白,作为目前妇科应用最广泛的肿瘤标志物,主要存在于间皮细胞组织、苗勒管上皮、间皮细胞及苗勒管衍生物发生的肿瘤中,如卵巢上皮癌、输卵管癌、子宫内膜癌、宫颈腺癌及间皮细胞癌等[8-9]。约85.0% 的晚期卵巢癌血清CA125升高,手术后和化疗奏效时水平下降,肿瘤复发会再度升高,因此广泛应用于卵巢上皮恶性肿瘤的临床诊断、疗效观察与监测[10-11]。其不足之处在于特异度不高,正常排卵期、子宫内膜异位症、子宫肌瘤、盆腔炎、卵巢过度刺激综合征、以及非卵巢癌的恶性肿瘤如肺癌、胃癌等状况下也会升高,导致假阳性;同时CA125在早期卵巢癌表达率较低,对浆液性癌以外恶性肿瘤如黏液性癌等的检出率也较低[8,11]

    本研究中CA125诊断的灵敏度较高,达到85.70%,但特异度、阳性预测值、阴性预测值及诊断准确率均较低,也说明单独应用CA125并不适合卵巢癌的筛查及早期诊断。

    HE4是一种人附睾分泌蛋白,在卵巢癌组织中表达水平明显升高,但在正常卵巢组织中一般不表达,在癌旁组织和良性肿瘤中有低水平的表达,因而是鉴别卵巢癌的新型肿瘤标志物,具有简单易测、创伤性小、受干扰因素少的优势[12-13]

    HE4在鉴别卵巢肿瘤的良恶性时准确率较高,尤其是对Ⅰ期卵巢癌的敏感度明显高于CA125,不足之处在于HE4对绝经前后肿瘤的诊断效能亦不同,绝经、年龄越大往往HE4水平有所升高因而对绝经前恶性肿瘤的诊断能力更高;此外多项研究证实HE4在卵巢透明细胞癌和黏液性癌中表达率较低[10-12],如联合CA125则能提高敏感性及特异度[14]

    本研究显示HE4诊断的灵敏度低于CA125,但特异度、阳性预测值、阴性预测值及诊断准确率均高于CA125,HE4联合CA125则具有较高的诊断效能,灵敏度、特异度及诊断准确率高于两者单独诊断。

    CT技术的发展有利于显示恶性肿瘤病变本身及继发改变的细节,从而及时诊断和准确分期[15-16]。总结本组资料并复习相关文献,我们认为卵巢上皮性恶性肿瘤的CT一般具有下述特征[4,17-18]:早期主要表现为囊性或囊实性,病情发展呈囊实性或部分实性;体积较大,一般直径大于4 cm;呈多房囊腔,肿瘤囊壁及囊腔内分隔厚薄不均匀,最大可超过3 cm;增强瘤体实性部分较明显强化,囊内可见明显强化的壁结节;后期往往伴有腹、盆腔积液及周边结构侵犯、淋巴结及远处转移,有时可见到较明显的肿瘤血管及两侧卵巢同时发病。

    本组CT诊断准确率为82.12%,对大部分Ⅱ期肿瘤和全部 Ⅲ、Ⅳ 期肿瘤均得以正确诊断及分期。漏诊者均为单发体积较小的Ⅰ、Ⅱ期囊性肿瘤,因为体积较小、实性成分少且强化不明显而误认为良性囊腺瘤;3例良性肿瘤因为体积较大且实性成分强化较明显而误诊为恶性。因此CT不能单独根据病灶大小、强化程度等对病灶性质进行判断。此外卵巢转移瘤和原发性肿瘤有时具有相似的CT表现,而肿瘤标志物CA125及HE4则可以一定程度上弥补CT的不足。

    本组资料证实,CT联合血清CA125及HE4对卵巢上皮恶性肿瘤诊断的灵敏度、特异度及准确率分别为95.21%、88.92% 及92.32%,明显高于单独的CT或肿瘤标志物检测。

    综上所述,CT联合血清CA125及HE4对卵巢上皮恶性肿瘤的诊断具有重要价值,有利于早期诊断及准确分期,从而为临床治疗提供可靠的依据,是术前鉴别卵巢上皮肿瘤良恶性的有效组合,值得临床推广应用。

  • 图  1   156例卵巢上皮肿瘤病例入组路线图

    Figure  1.   Enrollment diagram of 156 cases of ovarian epithelial tumors

    图  2   46岁女性,右侧卵巢黏液性囊腺癌

    Figure  2.   A 46-year-old female, mucinous cystadenocarcinoma in the right ovary

    图  3   70岁女性,右侧卵巢浆液性囊腺癌

    Figure  3.   A 70-year-old female, serous cystadenocarcinoma in the right ovary

    图  4   43岁女性,左侧卵巢透明细胞癌

    Figure  4.   A 43-year-old female,clear cell carcinoma in the left ovarian

    图  5   55岁女性,右侧卵巢子宫内膜样腺癌

    Figure  5.   A 55-year-old female, endometrioid adenocarcinoma in the right ovarian

    表  1   血清CA125、HE4在卵巢上皮良、恶性肿瘤组中阳性率的比较

    Table  1   Comparison among positive rates of serum CA125 and HE4 in benign and malignant ovarian epithelial tumors

    分组CA125HE4
    恶性肿瘤组(n=84)85.71%(72/84)80.95%(68/84)
    良性肿瘤组(n=72)38.89%(28/72)22.22%(16/72)
    χ${} ^2$36.9453.81
    P0.0000.000
    下载: 导出CSV

    表  2   CT、血清CA125、HE4单独及联合应用对卵巢上皮恶性肿瘤的诊断结果比较

    Table  2   Comparison among the diagnostic results of CT, serum CA125, HE4 alone and combination application in epithelial ovarian cancer

    诊断项目 灵敏度/%特异度/%阳性预测值/%阴性预测值/%准确率/%
    CA125     85.71a61.1172.0078.5774.36
    HE4      80.9577.78b80.95b77.7879.49b
    CA125+HE4  90.48c83.33c86.36c88.24c87.18c
    CT      83.3380.5683.3380.5682.05
    CT+CA125+HE495.24d88.89d90.91d94.18d92.31d
    χ2      9.8618.5912.999.9921.30
    P       0.0430.0010.0110.0410.000
     注:a-高于HE4;b-高于CA125;c-高于CA125、HE4及CT;d-高于CA125、HE4、CA125+HE4及CT。
    下载: 导出CSV
  • [1]

    GUPTA N, YADAV M, GUPTA V, et al. Distribution of various histopathological types of ovarian tumors: A study of 212 cases from a tertiary care center of Eastern Uttar Pradesh[J]. Journal of Laboratory Physicians, 2019, 11(1): 75−81. doi: 10.4103/JLP.JLP_117_18

    [2]

    HATANO Y, HATANO K, TAMADA K, et al. A comprehensive review of ovarian serous carcinoma[J]. Advances in Anatomic Pathology, 2019, 26(5): 329−339. doi: 10.1097/PAP.0000000000000243

    [3] 程亮亮, 刘哲, 于显凤. MSCT联合CEA、Ki-67及CA125检测对卵巢癌的诊断价值[J]. 中国CT和MRI杂志, 2021,19(3): 104−106. doi: 10.3969/j.issn.1672-5131.2021.03.035

    CHENG L L, LIU Z, YU X F. Diagnostic value of multi-slice spiral CT combined with CEA, Ki-67 and CA125 detection for ovarian cancer[J]. Chinese Journal of CT and MRI, 2021, 19(3): 104−106. (in Chinese). doi: 10.3969/j.issn.1672-5131.2021.03.035

    [4] 周康荣, 严福华, 曾蒙苏. 腹部CT诊断学[M]. 上海: 复旦大学出版社, 2010: 889-896.
    [5]

    RODRIGUEZ G M, GALPIN K J C, MCCLOSKEY C W, et al. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy[J]. Cancers (basel), 2018, 10(8): 242. doi: 10.3390/cancers10080242

    [6]

    TESTA U, PETRUCCI E, PASQUINI L, et al. Ovarian cancers: Genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells[J]. Medicines (basel), 2018, 5(1): 16.

    [7] 邓蕊, 刘晓峰. 卵巢癌术前新辅助化疗疗效及对肿瘤标志物的影响[J]. 中国现代医生, 2021,59(6): 13−16.

    DENG R, LIU X F. Efficacy of preoperative neoadjuvant chemotherapy for ovarian cancer and its influence on tumor markers[J]. China Modern Doctor, 2021, 59(6): 13−16. (in Chinese).

    [8]

    CHARKHCHI P, CYBULSKI C, GRONWALD J, et al. CA125 and ovarian cancer: A comprehensive review[J]. Cancers (Basel), 2020, 12(12): 3730. doi: 10.3390/cancers12123730

    [9]

    ZHAO T T, HU W P. CA125 and HE4: Measurement tools for ovarian cancer[J]. Gynecol Obstet Invest, 2016, 81(5): 430−435. doi: 10.1159/000442288

    [10]

    GUO N, PENG Z L. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study[J]. Journal of Ovarian Research, 2017, 10: 14. doi: 10.1186/s13048-017-0310-y

    [11]

    GU Z W, HE Y F, ZHANG Y, et al. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer[J]. Journal of Translational Medicine, 2018, 16: 114. doi: 10.1186/s12967-018-1489-4

    [12]

    YANG W L, LU Z, GUO J, et al. HE4 antigen-autoantibody complexes complement CA125 for detecting early stage ovarian cancer[J]. Cancer, 2020, 126(4): 725−736. doi: 10.1002/cncr.32582

    [13]

    RONG Y, LI L. Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer[J]. Journal of Ovarian Research, 2021, 14(1): 2. doi: 10.1186/s13048-020-00759-9

    [14] 李玮珊, 王丹波. 肿瘤标志物HE4在卵巢癌中的应用研究进展[J]. 现代肿瘤医学, 2019,27(6): 1095−1098. doi: 10.3969/j.issn.1672-4992.2019.06.047

    LI W S, WANG D B. Application of tumor marker HE4 in ovarian cancer[J]. Modernon Vcology, 2019, 27(6): 1095−1098. (in Chinese). doi: 10.3969/j.issn.1672-4992.2019.06.047

    [15] 冯莉, 陈伟彬, 李盖, 等. 多层螺旋CT对结肠癌淋巴结转移的诊断价值[J]. CT理论与应用研究, 2021,30(1): 124−130. DOI: 10.15953/j.1004-4140.2021.30.01.13.

    FENG L, CHEN W B, LI G, et al. The diagnostic value of multislice spiral CT in lymph node metastasis of colon cancer[J]. CT Theory and Applications, 2021, 30(1): 124−130. DOI: 10.15953/j.1004-4140.2021.30.01.13. (in Chinese).

    [16] 孙凤涛, 张厚宁, 禹璐, 等. MSCT评价小肠粪便征在小肠梗阻中出现的意义[J]. CT理论与应用研究, 2020,29(2): 249−256. DOI: 10.15953/j.1004-4140.2020.29.02.16.

    SUN F T, ZHANG H N, YU L, et al. Multi-slice CT evaluation of significance of small bowel feces sign in small-bowel obstruction[J]. CT Theory and Applications, 2020, 29(2): 249−256. DOI: 10.15953/j.1004-4140.2020.29.02.16. (in Chinese).

    [17]

    MARKO J, MARKO K I, SUVIDYA L. Pachigolla, mucinous neoplasms of the Ovary: Radiologic-pathologic correlation[J]. Radiographics, 2019, 39(4): 982−997. doi: 10.1148/rg.2019180221

    [18] 欧阳璟雯, 唐荣, 郑佳. 卵巢癌CT及超声影像特征与术后病理检查结果的比较分析[J]. 中国CT和MRI杂志, 2019,17(7): 110−112. doi: 10.3969/j.issn.1672-5131.2019.07.033

    OUYANG J W, TANG R, ZHENG J. CT and ultrasonic imaging features of ovarian cancer and comparison with postoperative pathological examination results[J]. Chinese Journal of CT and MRI, 2019, 17(7): 110−112. (in Chinese). doi: 10.3969/j.issn.1672-5131.2019.07.033

  • 期刊类型引用(6)

    1. 李新经,袁珊. CA199和HE4及VEGF在卵巢交界性和恶性上皮性肿瘤中的表达及诊断价值. 医药论坛杂志. 2025(02): 211-215 . 百度学术
    2. 王丽雯,李静芳,李晓红,余鑫. 血清miR-200c表达水平与复发性卵巢癌的相关性及临床意义. 中国性科学. 2024(03): 58-61 . 百度学术
    3. 岳红 ,汤进 ,陈钢 . 血清ALP、HE4联合SII指数与卵巢癌肿瘤良恶性程度相关性及预后影响因素分析. 临床和实验医学杂志. 2024(22): 2412-2416 . 百度学术
    4. 张建泉,符纪宁,蔡淑华,沈智勇. 卵巢癌MRI表现与Ki-67表达及预后的关系. 中国CT和MRI杂志. 2023(06): 130-132 . 百度学术
    5. 王丽雯,李静芳,李晓红,余鑫,杨伟,高艳章. 上皮性卵巢癌患者血清miR-200a、miR-200b水平变化及意义. 山东医药. 2023(26): 58-61 . 百度学术
    6. 谢敏霞,林琳. HE4与CA125联合检测在妇科肿瘤诊断中的作用评价. 深圳中西医结合杂志. 2023(15): 64-67 . 百度学术

    其他类型引用(0)

图(5)  /  表(2)
计量
  • 文章访问数:  250
  • HTML全文浏览量:  63
  • PDF下载量:  24
  • 被引次数: 6
出版历程
  • 收稿日期:  2021-08-08
  • 网络出版日期:  2022-03-23
  • 发布日期:  2022-09-30

目录

/

返回文章
返回
x 关闭 永久关闭